Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery

PHASE3TerminatedINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

December 18, 2023

Primary Completion Date

May 2, 2024

Study Completion Date

May 9, 2024

Conditions
Inflammation EyePain, PostoperativeCataract
Interventions
DRUG

Dexamethasone Ophthalmic Suspension

Ophthalmic Suspension,1.5% \[15 mg/mL\] Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).

OTHER

Vehicle of OCS-01

inert vehicle of OCS-01 ophthalmic suspension Subjects will dose 1 drop of OCS-01 in the study eye once daily for 14 days, beginning 1-day post-surgery in the operated eye (administration of first dose will be performed in the clinic on Day 1).

Trial Locations (12)

18704

Oculis Investigative Site, Kingston

24502

Oculis Investigative Site, Lynchburg

27909

Oculis Investigative Site, Elizabeth City

30260

Oculis Investigative Site, Morrow

40206

Oculis Investigative Site, Louisville

63090

Oculis Investigative Site, Washington

63131

Oculis Investigative Site, St Louis

77008

Oculis Investigative Site, Houston

78229

Oculis Investigative Site, San Antonio

78731

Oculis Investigative Site, Austin

90301

Oculis Investigative Site, Inglewood

97401

Oculis Investigative Site, Eugene

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Oculis

INDUSTRY

NCT06128369 - Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery | Biotech Hunter | Biotech Hunter